HR-EEG Contribution in Prognostic Evaluation of Language Development in Children With ASD
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3-4
SponsorEtablissement Public de Santé Barthélemy Durand
About this trial
The goal of this prospective observational multicentric cohort study is to evaluate the clinical prognostic value of the speech tracking score of language development in children with ASD aged from 3 years to 4 years and half at inclusion.
Participants will followed during 4 years with an annual visit. During these visits, each participant will be clinically evaluated (scales and tests) and performed an EEG-HR recording. Two groups will be formed, one with children diagnosed with ASD with language delay, and a control group composed of non-ASD children without language delay, matched on age and gender with the ASD group.
Eligibility criteria
Qualifiers
Child aged from 3 years to 4 years and half at inclusion.
Information delivered and no parental objection for study participation.
Diagnosis of ASD according to DSM-V criteria.
Expressive language level < 27 months regarding on IDE scale.
Disqualifiers
Any illness or treatment that could significantly alter EEG-HR recording (epilepsy, anti-epileptic treatment, psychotropic drugs...).
Major hearing or vision disorders.
Characterised neurological or psychiatric pathology.
Characteristic language delay.
Trial design
Treatments tested in this trial
- EEG-HR
- ADI-R
- ADOS-2
- IDE
- MSEL
- Dunn
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov